Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Israel, EU Reach Trade Agreement On Easing Drug Availability To U.K.

This article was originally published in PharmAsia News

Executive Summary

Israel and the European Union have reached a trade agreement designed to allow Israeli drug makers to market their products more easily in the United Kingdom.

Israel and the European Union have reached a trade agreement designed to allow Israeli drug makers to market their products more easily in the United Kingdom. The European Parliament approved the Agreement on Conformity Assessment and Acceptance of Industrial Products despite pressure to reject it waged by the Palestine Solidarity Campaign and Liberal Democrat Friends of Palestine. Sarah Ludford, known as the Liberal Democrat MEP baroness, challenged other-party assertions her group was weak on the issue. (Click here for more)

"MEPs Vote To Remove Drug Trade Barriers" - The Jewish Chronicle (10/25/2012)

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

SC079666

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel